iPLEDGE REMS Modifications Have Been Implemented and Are Live for Isotretinoin, a Medication for Severe Acne

The iPLEDGE Risk Evaluation and Mitigation Strategy (REMS) modifications were implemented yesterday, November 15, 2026. The iPLEDGE REMS is a safety program to mitigate the risk of isotretinoin, which can result in harm to fetal development. Isotretinoin is approved to treat severe nodular acne that has not responded to other treatments in non-pregnant patients 12 years and older.